Testosterone replacement therapy after radiation therapy

Many urologists these days are fairly comfortable prescribing testosterone replacement therapy (TRT) for men who have had a radical prostatectomy and whose PSA has stayed at undetectable levels for some time. However, … READ MORE …

Testosterone therapy and risk for prostate cancer (redux)

The question of whether long-term exposure to testosterone therapy is associated with a significant increase in risk for a diagnosis of prostate cancer (and particularly clinically significant or high-risk prostate cancer) remains a matter of debate. … READ MORE …

Low serum T and high-risk prostate cancer in Korean men

A group of Korean researchers have poublished data suggesting that — at least in Korean patients — there may be an association between having a low serum testosterone (serum T) level and diagnosis with high-grade prostate cancer. … READ MORE …

Other items from the annual meeting of the AUA

A combination of travel and other commitments made it difficult for your sitemaster to complete his summaries of significant information presented at this year’s annual meeting of the American Urological Association (AUA), so here’s the final wrap-up. … READ MORE …

ADT, patient survival, and serum testosterone levels after initiation of treatment

Over the years there have been multiple debates about whether different types of androgen deprivation therapy (ADT) really do or don’t extend the survival of men with advanced prostate cancer of differing types and whether the degree to which ADT initially suppresses serum testosterone levels affects that survival. … READ MORE …

TRT and prostate cancer risk in hypogonadal men

A new paper in the Journal of Urology provides data from European males with clinically low levels of serum testosterone indicating that, in these patients, testosterone replacement therapy (TRT) was not associated with any increase in risk for a diagnosis of prostate cancer. … READ MORE …

Testosterone supplements, rats, and risk for prostate cancer in healthy, aging men

The “New” Prostate Cancer InfoLink has long argued that the use of testosterone supplements by otherwise healthy men as they age (as a way to try to maintain the vigor and libido of their youth) comes with risks, and that one of those risks is the risk for a diagnosis of prostate cancer. … READ MORE …

Is baseline free serum T a factor in appropriate management on active surveillance?

Analysis of data from a cohort of 154 Chilean men with prostate cancer, all being monitored on active surveillance, suggests that free serum testosterone levels (but not total testosterone levels) may be able to help to predict which of these men will go on to need active treatment. … READ MORE …

Efficacy of continuous ADT and correlation to nadir serum T levels

We had “missed” a poster presented at the recent meeting of the European Urology Association that appears to “put to bed” — in a positive fashion — the question of a relationship between nadir serum testosterone (T) levels in men on continuous androgen deprivation therapy (ADT) and the long-term effectiveness of continuous ADT. … READ MORE …

What is the appropriate serum T threshold for medical “castration”?

For many years, the formal threshold level of serum testosterone (T) used to define medical “castration” has been < 50 ng/dl. However, it is widely recognized that this level is probably not low enough to accurately define a medically castrate state. … READ MORE …

Supplemental testosterone therapy in men treated for prostate cancer

The role of supplemental testosterone therapy in men previously treated for prostate cancer has long been a controversial issue, and the number of patients actually studied for the effects of such therapy (good and bad) is really quite small — at about 600 worldwide. … READ MORE …

A very different way to project risk for clinically significant prostate cancer?

We don’t want to suggest that the recent paper by a Japanese research team in the journal Andrology is necessarily going to revolutionize the diagnosis of clinically significant prostate cancer. A great deal more work would be required to justify the hypothesis that they put forward. On the other hand, their hypothesis is definitely interesting. … READ MORE …

TRT after radical prostatectomy for localized prostate cancer in hypogonadal males

A new paper just published in the Journal of Urology addresses (again) the controversial issue of whether the use of testosterone replacement therapy (TRT) is appropriate as a management strategy after first-line treatment for hypogonadal patients. … READ MORE …

Testosterone supplementation and prostate cancer risk

In case you haven’t noticed, there has been a massive surge in the use of testosterone supplements by older men in the past 10 years or so (as we seek to maintain the bizarre illusion that we are really still in our early 30s and might still be able to win an Olympic gold medal in [pick your sport]). … READ MORE …

Sexual function and serum T levels, before, on, and after 9 months of ADT

As many readers of this news service will be aware, good data on the recovery of libido and sexual function after a period of androgen deprivation therapy (ADT) are limited. We have long known that such recovery is variable, and we also know that it can take time, but sound data from a large cohort of patients has been “missing in action,” so to speak. A new paper by Ng et al. has now remedied this problem. … READ MORE …